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VALUE BASED PRICING: WHAT IS THE FUTURE FOR PATIENT ACCESS
SCHEMES?
Loveman CM, Mallinson M, Areteou T, White R
Double Helix Consulting, London, UK
OBJECTIVES: In the face of universal budget restrictions, pricing of pharmaceuti-
cals remains a divisive subject. TheUS government is increasing its involvement in
healthcare provision and insurers will have more budget pressures due to in-
creased coverage. In the UK, the government has proposed a value based pricing
approach which will potentially increase the availability of new drugs. The objec-
tive of this research is to better understand the future outlook for patient access
schemes (PAS) in achieving affordable budget impact whilst not restricting patient
access. METHODS: 40 telephone interviews were undertaken with payers in the
UK, US and Taiwan representing government agencies, HTA groups and insurers.
We asked interviewees about their perceptions of PAS policies to provide required
value evidence, improve affordability, strategies that could be used by manufac-
turers and likely future changes. RESULTS: Results demonstrated that manufac-
turers will aim for a particular price or price threshold; if this is not accepted by
payers, outcome-based schemes or other flexible pricing arrangements would be
proposed for manufacturers to establish that their product is cost-effective and to
achieve revenue targets. UK payers will find it difficult to determine the level of
weighting applied to different unmet needs or to assign various rewards on value.
Respondents stated that PAS could be a method used to determine the level of
value through monitoring outcomes, but administrative burdens need to be con-
sidered. In the US, market evolution will accelerate the uptake of patient access
schemes. Taiwan is likely to introduce PAS approaches as a means to reduce ex-
penditure on high cost drugs. CONCLUSIONS: The current budget constraints in
the different countries may lead to an increased interest in implementing PAS,
which in turn may change the way health systems look at value for patients.
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WHICH CRITERIA ARE USED IN HEALTH CARE DECISIONMAKING AND
PRIORITY SETTING? A LITERATURE REVIEW FOR AN INTERNATIONAL SURVEY
OF DECISIONMAKERS
Guindo LA1, Wagner M2, Baltussen R3, Rindress D2, Van Til J4, Kind P5, Goetghebeur M2
1MSc Candidate, Montreal, QC, Canada, 2BioMedCom Consultants Inc., Dorval, QC, Canada,
3Radboud University, Nijmegen, The Netherlands, 4University of Twente, Enschede,
The Netherlands, 5University of York, York, UK
OBJECTIVES: Resource allocation is one of the most challenging issues faced by
health policy decision-makers requiring efficient consideration of many factors.
Objectives of this study are to identify criteria used in decisionmaking around the
world. METHODS: An extensive literature search was performed in Medline and
EMBASE to identify articles reporting decision criteria. Bibliographies of relevant
articles were also searched. Studies conducted with healthcare decisionmakers
(e.g., empirical studies, field-testing of decisionmaking tools, focus groups, ques-
tionnaires, interviews), conceptual and reviews articles as well as articles describ-
ing decisionmaking tools were included. Criteria reported were extracted and or-
ganized using a classification system derived from the EVIDEM framework.
RESULTS: A total of 2903 records were identified through database searching and
243 additional records were identified through bibliographic hand searching; of
these 2790 were excluded. 356 articles were assessed for eligibility and 40 articles
were included in the study. Large variations in terminology used to defined criteria
were observed and 338 different terms were identified. These were assigned to 58
unique criteria which were classified in 9 different categories including: 1) health
outcomes and benefits of intervention, 2) types of health benefit, 3) impact of
disease targeted by intervention, 4) therapeutic context of intervention, 5) eco-
nomic impact of intervention, 6) quality/uncertainty of evidence, 7) implementa-
tion complexity of intervention, 8) priority, fairness and ethics, 9) overall context.
The most frequently mentioned criteria were: equity/fairness (33 times), efficacy/
effectiveness (28), healthcare stakeholder interests and pressures (28), cost-effec-
tiveness (23), strength of evidence (20), safety (19), mission and mandate of health
system (17), need (16), organizational requirements and capacity (17) and patient
reported outcomes (16). CONCLUSIONS: The data synthesized in this study will
serve as the basis for development of an international survey of healthcare deci-
sionmakers. The ultimate objective is to develop multicriteria approaches to effi-
cient healthcare decisionmaking and priority setting.
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COMPARATIVE EFFECTIVENESS REVIEWS AND THEIR POTENTIAL IMPACT ON
FORMULARY ACCESS IN THE UNITED STATES
Xia AD
HERON Evidence Development Ltd, London, UK
OBJECTIVES: The Effective Health Care Program of the AHRQ (Agency for Healthcare
Research and Quality) has sponsored various comparative effectiveness reviews. The
outcomes of these reviews were examined to determine their impact on access of
drugs in the US and potential future impact as the role of HTA becomes increasingly
important. METHODS: Initially, we examined the AHRQ online database and com-
piled a list of conclusions from completed comparative effectiveness reviews in vari-
ous therapy areas. Then, we compared these conclusions to the current access of
these therapies in a selection of the largest US plans by lines covered (Aetna, United-
Health, Cigna, Kaiser, Wellpoint) using their online formulary databases. RESULTS:
ACEIs vs. ARBs, NSAIDs, anti-depressants, epoetins, PPIs vs. H2As, and statins were
reviewed by the AHRQ. Some of these resultswere either inconsistent or inconclusive
due to lack of evidence; however, several found efficacy and safety to be similar across
agents in a class. As expected, access to these productswithin the largest US plans are
also comparable. In certain instances, a specific product or class demonstrated supe-
rior efficacy or tolerability. PPIs showed greater efficacy than H2As in resolution of
reflux disease, and more specifically, esomeprazole demonstrated superior efficacy
over omeprazole for relief of symptoms at 4 weeks. Topical NSAIDs, such as diclofe-
nac, demonstrated comparable efficacy to orals with fewer tolerability issues. How-
ever, these superiorities are not always reflected in the formulary access of these
products in terms of tier placement or restrictions. CONCLUSIONS: It appears that
these comparative effectiveness reviews by the AHRQ have some indirect impact on
formulary access in theUS.However, price and contracting, in addition to efficacy and
safety are among the key determinants for plans. It will be necessary to continue
monitoring these reviews moving forwards and attempt to filter out their direct im-
pact on access of drugs over time.
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CURRENT USES OF AND PERCEPTIONS ABOUT FDAMA SECTION 114
Lin PJ1, Hughes TE2, Neumann PJ1
1Tufts Medical Center, Boston, MA, USA, 2i3 Innovus, Carmel, IN, USA
OBJECTIVES: Section 114 of the 1997 U.S. Food and Drug Administration Moderniza-
tion Act (FDAMA) stipulates the conditions under which drug companies could pro-
mote health economic information to health care plans. This study examined current
uses of and perceptions about Section 114. METHODS: We conducted a web-based
surveyof a convenience sampleof 59experts representingpharmaceutical companies
and academia. We asked about their interpretation of, and experiences with, Section
114, as well as their views regarding the FDA issuing further guidance to advise phar-
maceutical companies onmaking promotional economic claims to payers. RESULTS:
Thirty-three of the 59 experts (56%) completed the survey. Among pharmaceutical
company health outcomes directors, 81% stated they always or frequently consider
using Section 114 when making promotional claims for drugs, but 63% stated they
were unclear about how to effectively create, approve or use Section 114 information.
The reasons for not using Section 114 included: not feeling comfortable using the
Section (25%); the fact that economic value information not included in the product
label (13%); and uncertainty aboutwhether creating a Section 114 piecewasworth the
benefit (13%). 75% expected to use Section 114 to a greater extent in the future. 75% of
outcomes director and 88% of academic experts stated that the FDA should issue
guidance on Section 114, especially regardingwhat qualifies as “health care economic
information” and “competent and reliable scientific evidence.” 69%of outcomesdirec-
tors and 65% of academic experts agreed that the increased focus on comparative
effectiveness research would increase Section 114 use. CONCLUSIONS: Pharmaceu-
tical companies are considering and using FDAMA Section 114 to make promotional
economic claims for drugs, despite their diverse interpretations of the law. Direction
from the FDA may clarify how companies could share a range of comparative eco-
nomic information with health plans.
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HOW ARE COVERAGE DECISIONS MADE IN PUBLICLY FUNDED HEALTH CARE
PROGRAMS IN LOW- AND MIDDLE-INCOME COUNTRIES?
Hornberger J, Shewade A, Gutierrez H
Cedar Associates LLC, Menlo Park, CA, USA
OBJECTIVES: Universal health coverage for all persons worldwide was the focus of
the First Global Symposium on Health Systems Research (Montreux, Switzerland;
Nov 2010). As part of a larger initiative sponsored by The Rockefeller Foundation to
transform health systems (accessible, affordable, equitable), we studied how cov-
erage decisions are made by publicly funded health care programs in low- and
middle-income countries (LMICs).METHODS: An online survey was administered
to representatives of 30 health care programs in LMICs. In-depth case studies,
based on ethnographic research methodologies, were conducted on a subset of
programs to address the following research questions: Who is covered in the pro-
gram? What health conditions and services are covered? What are the cultural,
political, ethical, scientific, and economic factors that influence coverage deci-
sions? What are the administrative processes for coverage decisions? What evi-
dence is used to determine coverage? What processes are used to monitor
outcomes? RESULTS: Maternal health, cardiovascular diseases, and preventing
catastrophic illness that results in large financial burden to the public tend to be the
highest priority conditions for coverage. Dental care and treatment for substance
abuse are the least commonly covered conditions.Most programsprovide coverage
for drugs; policies for drugs are basedmostly on published reports of clinical safety
and efficacy. Factors influencing decisions included limiting the financial risk from
catastrophic illness, ability to scale programs, and equity issues. Evidence used for
coverage decisions was based on medical literature, regional and global health
research, and coverage policies of other programs. Some programs undertake eco-
nomic appraisals and comparative effectiveness assessments in determining
policies. CONCLUSIONS: This ethnographic survey on how coverage policies are
being developed provides opportunities for LMICs to share their experiences with
each other, and thus further develop and refine their programs to meet goals of
accessible, affordable, and equitable heath care for all.
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DISPARITY IN ACCESS TO NOVEL DIABETIC AGENTS FOR MEDICARE PART D
ELDERLY COMPARED TO COMMERCIAL INSURED PATIENTS: INSIGHT INTO
DOWNSTREAM EFFECTS OF CMS FORMULARY COVERAGE GUIDELINES FOR
PDP’S
Schwartz EL1, Davis EA1, Belazi D2, Hasan S2
1PriceSpective, San Diego, CA, USA, 2Wolters Kluwer Pharma Solutions, Yardley, PA, USA
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BACKGROUND: As age increases, prevalence of type 2 diabetes in the U.S. rises
dramatically as the population approaches and enters Medicare eligibility (CDC).
Although ensuring category access, CMS formulary guidelines for Medicare Part D
(MPD) coverage do not take into account the effects of cost-sharing burden on
patient compliance. Literature demonstrates that patient adherence is reduced
with higher copayment costs and consequently, the beneficial clinical impactsmay
likely be unrealized for many patients. OBJECTIVES: To investigate access to dia-
betic medications for MPD patients compared to commercially covered lives. Ex-
ploring copay differentials amongst these populations, insight is gained on how
MPD differs from commercial access to diabetes medications.METHODS: Analysis
of the Walters Kluwer Pharma Solutions Source Longitudinal Patient Database,
sampling of 26.7 million commercial lives and 5 million Medicare Part D lives in
2009. Low Income Subsidy covered lives were excluded. RESULTS: Average drug
copayment for metformin and sulfonylurea for commercial and MPD patients is
$15 and $19 respectively. Average drug copayment for insulin glargine in commer-
cial is $17 and $27 for MPD patients, for branded pioglitazone $31 and $52, and
exenatide $32 and $68. CONCLUSIONS: Copayment differentials across these pop-
ulations are small for generic therapies and grow larger for branded, novel diabetic
agents. This data would suggest a broader, more inclusive review is needed to
assess how the financial burden felt by MPD diabetes patients affects patient com-
pliance and outcomes. Further investigation is needed to study the potential value
that CMS would benefit from re-evaluating the cost sharing burden for this patient
population.
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BIOMARKERS: A CHANGING PARADIGM FOR DEVELOPMENT
Pardini AT, Saraf S, Sparrowhawk K
PriceSpective Ltd., London, UK
The general perception is that pharma companies generally incorporate biomarker
(BM) development into their processes when a drug response is not optimal follow-
ing the results of phase 3 studies. Usually this is when poorer than expected effi-
cacy results are achieved. In this scenario, the BM development enables targeting
of a niche population that is representative of the responders, thus effectively
increasing the efficacy making the product more attractive to payers and health-
care professionals. This late stage approach to BM development also fits with the
commonly held belief that BMs are linked to reduced market access (MA), lower
market shares and decreased product revenues. In such a situation BMs are often
only developed retrospectively to overcome access issues. Our objective is to dem-
onstrate that investment into BMs in the early phase of drug development (DD) is
more commercially attractive. METHODS: Three scenarios of drug development
were defined: 1) the current/traditional model, 2) where biomarker development
is incorporated from phase I of development and 3) where biomarker develop-
ment involves a concurrent Phase III investigation or Phase IV retrospective
analysis. These scenarios were analyzed to determine the relationship between
risk and reward using assumed cash-flow curves and net-present value analysis
based upon those curves. In each case, the implications of integration of BM
development at various stages and how this affects risk-reward were assessed.
RESULTS AND CONCLUSIONS: The scenario analysis demonstrates that by shift-
ing investment to earlier in the DD process, costs associated with investment-
heavy Phase III will be reduced. Early incorporation of BMs into DDwill improve the
commercial and healthcare benefits and the drug will have the potential to benefit
from shortened approval time, early MA and higher price.
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THE CASE OF RARE DISEASE DRUGS BEFORE AND AFTER THE INTRODUCTION
OF PRICING BODIES: LESSONS LEARNED FROM BRAZIL AND CANADA,
IMPLICATIONS FOR THE UNITED STATES
Cost P, Snyder T, Zaidi Q
HERON Evidence Development LLC, Somerville, NJ, USA
OBJECTIVES: This poster examines the pharmaceutical price implication for rare
disease products in two countries which recently developed technology assess-
ment and pricing processes with a look toward the potential implications for the
United States. METHODS: Case studies are built out of examining prices for the
Multiple Sclerosis drugs interferon beta-1a and natalizumab in the context of Bra-
zil, while the Gaucher’s disease products imiglucerase andmiglustat are studied in
Canada. In each case, a brief overview of the health systems is given, with specific
attention to the pricing bodies. The prices for drugs which came to market before
and after the advent of a pricing body are compared relative to each other. These
differences are then compared to the price differential in the US and UK to deter-
mine if the HTA bodywas instrumental in this pricing change. RESULTS: In Canada
miglustat is 17.8% of the cost for imiglucerase while in the US it is 38%, with a
similar trend in the price of MS drugs in Brazil. To some degree, the lower price is
expected as the drug classes are different. However, the disparity between a 17.8%
differential and a 38% differential suggests that the Canadian pricing body is used
to apply downward pressure on the price of rare disease drugs.CONCLUSIONS:The
price differential has distinct implications for the USmarket, in which payers may
look towards developing a technology assessment process using cost effectiveness
research to drive down costs due to the current environment. As one of the most
important markets for pharmaceutical profits, this has considerable ramifications
for industry in terms of income and innovation incentive.
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AN OUTCOMES PROFILE REGISTRY FOR ESTABLISHING A BASELINE MATRIX IN
COMPARATIVE EFFECTIVENESS STUDIES IN PREDICTIVE PHARMACOLOGY
Wheeler C
NTELX, Inc, Vienna, VA, USA
We propose a novel applied decision analytics solution in clinical outcomes anal-
ysis for deriving outcomes to be used as benchmarks in designing appropriate
therapies in personalized medicine and predictive pharmacology. The efficacy of
comparative effectiveness research in clinical medicine and pharmacology is lim-
ited by the lack of a defined solution to derive clinical outcomes across diverse
patient populations and a variety of disparate data sources that collectively define
a clinical profile at particular point in time. An outcome at timeT1 is driven not only
by static factors such as race, ethnicity and occupation, that are generally time-
independent, but also by the condition profile and resultant outcome of the pa-
tient’s condition at T0. Our solution is an ensemble analytical framework that
leverages a temporal rule induction algorithm to create derived outcomes profiles
across the time continuum. It performs analysis on structured and unstructured
data from EMR/EHR, clinical, biological, biomarker, behavioral and demographic
data sources that are integrated into a composite data warehouse via our propriety
semantic resolution and natural language processing algorithms. The outcomes
profiles reflect an index or aggregate score for the amalgamation of all available
data for a particular patient at a particular time. Outcomes profiles from thousands
of samples are catalogued and normalized in a registry and are used to establish a
baselinematrix for application in higher level statistical and predictive analyses for
comparative effectiveness studies in pharmacology. Using this approach, it is pos-
sible to determine based on available data both the appropriate treatment to affect
a desired outcomeand the predicted outcomebased on a given treatment at a given
time.
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BIOSIMILARS LITERATURE REVIEW: THE CURRENT LANDSCAPE AND
IMPLICATIONS OF RECENT HEALTH CARE LEGISLATION FOR THE UNITED
STATES MARKET
Maiese BA, Lee EH, Toscani MT
Jefferson School of Population Health, Philadelphia, PA, USA
Biosimilars represent an emerging area of interest for the pharmaceutical industry.
Biosimilars are essentially ’generic’ versions of ‘branded’ biologics, but are not
considered identical to the innovator biologic. In 2009, half of the top ten selling
drugs were biologics; this proportion is expected to reach 80% by 2015. Biosimilars
are seen as a cost-saving alternative to payers, and as generic drugs take over the
market, manufacturers are depending on biologics to drive growth. However, they
will need to consider the inherent challenges in this market. This literature review
was undertaken to provide a summary of the current state of affairs with biosimi-
lars, including a review of the recent healthcare legislation and policies in coun-
tries that already have formal guidance regarding biosimilars approval. Significant
resources are required to participate in the biosimilars market, including regula-
tory expertise, manufacturing capabilities, and global market reach. One concern
to potential market players is the uncertainty regarding the approval process for
biosimilars in the United States (U.S.). The Patient Protection and Affordable Care
Act (PPACA 2009) authorized the FDA to develop an abbreviated regulatory path-
way for biosimilar approval but guidance has not yet been issued. It is important for
the U.S. to learn from other countries. This review includes a summary of other
countries’ approaches to biosimilars approval. For example, since 2006, the Euro-
pean Medicines Agency has had extensive requirements for pre-clinical and clini-
cal data to demonstrate quality, safety, and efficacy of the product seeking ap-
proval. Questions remain including: How will the competitive landscape look as
biosimilars enter the market? What will be the comfort level with substitutability
of biosimilars?Will there be patent protection for themanufacturing process? And,
what will the FDA require in terms of clinical trials and other supportive data to
recognize biosimilars? The literature review will address these questions and
more.
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OVER INFLATION OF THE GENETIC CONTRIBUTION TO SCHIZOPHRENIA:
IMPLICATIONS FOR NOVEL THERAPEUTICS
Fleming M, Martin CR
University of the West of Scotland, Ayr, UK
The biologicalmodel of schizophrenia remains the dominantmodel withinmental
health services andhas a powerful and enduring influence on the prevailing format
of mental health care delivery to patients with the diagnosis. There exists almost
universal acceptance of a genetic cause for schizophrenia though in many in-
stances this conflicts both philosophically and clinically with a person-centred
recovery orientated approach. A reviewof the underpinning research that supports
the genetic argument was conducted. Appraisal of family, twin and adoption stud-
ies uncovers serious flaws in the methodologies and statistical analyses used in
studies. These flaws tend to artificially inflate the perceived genetic contribution to
schizophrenia and moreover may also invalidate many of the reported study find-
ings. There exists an absence of a replicable and consistent finding indicating a
clear genetic pathway to schizophrenia. Novel therapeutic approaches aimed at
neurotransmitter receptor site abnormalities should not therefore be discouraged
by any fundamental refocus on gene therapy approaches.
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DEFINITIONAL CRITERIA FOR CHRONIC FATIGUE SYNDROME: A CRITICAL
REVIEW
Christley Y, Duffy T, Martin CR
University of the West of Scotland, Ayr, UK
Chronic Fatigue Syndrome (CFS) is an enigmatic andmisunderstood clinical entity.
A broad range of etiologicalmechanismshave been suggested including endocrine,
immune, infectious, muscular and neurological abnormalities. However, the cause
remains elusive thus impacting on developing models of evidenced based thera-
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